Table 4 Impact of MTHFR C677T on serum lipid levels according to lipid status (mmol/L)

LG

Dyslipidemia

CC

167

5.84 ± 0.76

1.14 (0.69)

1.68 ± 0.39

3.57 ± 0.74

CT

84

5.96 ± 0.75

1.16 (0.71)

1.70 ± 0.41

3.66 ± 0.70

TT

10

6.30 ± 1.14

1.13 (1.10)

1.72 ± 0.66

3.80 ± 0.89

F

—

1.265

0.120

0.501

0.431

p

—

0.284

0.887

0.607

0.605

CC

167

5.84 ± 0.76

1.14 (0.69)

1.68 ± 0.39

3.57 ± 0.74

CT/TT

89

5.99 ± 0.81

1.16 (0.72)

1.71 ± 0.44

3.67 ± 0.72

F

—

1.001

0.041

0.232

0.625

p

—

0.318

0.839

0.631

0.430

Normolipidemia

CC

165

4.38 ± 0.58

0.85 (0.33)

1.51 ± 0.32

2.49 ± 0.62

CT

75

4.38 ± 0.65

0.85 (0.28)

1.51 ± 0.32

2.45 ± 0.52

TT

15

4.35 ± 0.69

0.94 (0.47)

1.45 ± 0.36

2.48 ± 0.57

F

—

0.021

0.228

0.240

0.222

p

—

0.979

0.796

0.786

0.801

CC

165

4.38 ± 0.58

0.85 (0.33)

1.51 ± 0.32

2.49 ± 0.62

CT/TT

90

4.38 ± 0.65

0.85 (0.34)

1.50 ± 0.33

2.46 ± 0.53

F

—

0.029

0.350

0.109

0.149

p

—

0.865

0.555

0.742

0.700

Non-LG

Dyslipidemia

CC

168

5.65 ± 0.92

1.16 (0.98)

1.71 ± 0.45

3.19 ± 1.00

CT

53

5.77 ± 0.59

1.11 (1.06)

1.68 ± 0.43

3.43 ± 0.61

TT

6

5.85 ± 0.39

0.85 (0.55)

2.19 ± 0.49

3.12 ± 0.46

F

—

0.307

1.270

1.880

0.501

p

—

0.736

0.283

0.155

0.606

CC

146

5.71 ± 0.66

1.16 (0.98)

1.71 ± 0.41

3.43 ± 0.64

CT/TT

58

5.76 ± 0.58

1.08 (1.13)

1.70 ± 0.42

3.45 ± 0.58

F

—

−0.530

−0.443

0.121

−0.148

p

—

0.597

0.658

0.903

0.883

Normolipidemia

CC

200

4.40 ± 0.50

0.80 (0.34)

1.74 ± 0.36

2.29 ± 0.52

CT

54

4.36 ± 0.58

0.69 (0.32)

1.65 ± 0.39

2.37 ± 0.56

TT

12

3.79 ± 0.90

0.79 (0.24)

1.53 ± 0.33

1.86 ± 0.70

F

—

7.662

0.987

1.272

5.337

p

—

0.001

0.374

0.282

0.005

CC

200

4.40 ± 0.50

0.80 (0.34)

1.74 ± 0.36

2.29 ± 0.52

CT/TT

66

4.26 ± 0.68

0.75 (0.33)

1.63 ± 0.38

2.27 ± 0.61

F

—

1.478

1.202

1.339

0.156

p

—

0.225

0.274

0.248

0.694